- Home
- / Arcturus Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Arcturus Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$19.1
2024-10-29
Market Capitalization
$529.2 M
2024-10-29
Revenue
$82 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 20.8M | 9.5M | 12.4M | 206.0M | 166.8M | 152.3M | 82.0M |
| General and administrative expense | 12.7M | 23.2M | 41.5M | 46.1M | 52.9M | 52.8M | 46.1M |
| Operating expense total | 46.3M | 81.1M | 193.8M | 248.0M | 158.3M | ||
| EBIT | (25.5M) | (71.5M) | (202.9M) | 12.2M | (78.2M) | (95.7M) | (76.3M) |
| EBIT margin, % | -122.7% | -749.8% | 5.9% | -62.8% | -93.0% | ||
| Investment income | (32.0K) | (263.0K) | 515.0K | (515.0K) | |||
| Interest expense | 2.1M | ||||||
| Pre tax profit | (26.0M) | (72.1M) | (203.7M) | 10.6M | (27.9M) | 81.1M | (65.8M) |
| Income tax expense | 1.3M | 1.8M | (4.0K) | ||||
| Net Income | (26.0M) | (72.1M) | (203.7M) | 9.3M | (29.7M) | (80.9M) | (65.8M) |
| EPS | 0.4 | (1.0) | (3.0) | (2.4) |